Nxera Pharma Reaches Key Milestone in Eli Lilly Collaboration

The latest announcement is out from Sosei Group ( (JP:4565) ).

Nxera Pharma has achieved a significant development milestone in its collaboration with Eli Lilly, targeting diabetes and metabolic diseases. This milestone, achieved through Nxera’s NxWave™ platform, validates their drug design capabilities and results in an undisclosed payment from Lilly. The collaboration, initiated in 2022, aims to leverage Nxera’s expertise in GPCR-focused drug design and Lilly’s development and commercialization capabilities. This achievement positions Nxera for potential future milestones and royalties, enhancing its industry positioning and offering promising implications for stakeholders.

The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally. The company has established a commercial business in Japan to develop and commercialize innovative medicines and has a pipeline of over 30 active programs targeting neurology, metabolic diseases, and immunology. Nxera employs approximately 400 people across key locations and is listed on the Tokyo Stock Exchange.

YTD Price Performance: -13.36%

Average Trading Volume: 956,140

Technical Sentiment Signal: Sell

Current Market Cap: Yen82.07B

Find detailed analytics on 4565 stock on TipRanks’ Stock Analysis page.